1 Min Read
April 18 (Reuters) - Cellectar Biosciences Inc
* Cellectar Biosciences receives Japanese patent for CLR 131 and CLR 125 for treatment of cancer stem cells Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.